Study
Ibrutinib induces a global chromatin reorganisation in chronic lymphocytic leukaemia
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001002827 | Other |
Study Description
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL. We have undertaken a detailed analysis of the changes happening to the chromatin structure in CLL cells from patients continuously receiving oral doses of ibrutinib. ChIP-seq has been performed for H3K4me3, H3K27ac, H3K27me3 and EZH2 . We observed that Ibrutinib-dependent lymphocytosis correlates with a global and transient recruitment of EZH2 to active cis-regulatory elements and increased H3K27me3.
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001004063 |
EZH2, H3K4me3, H3K27ac and H3K27me3 ChIP-seq data consisting of fastq single-end reads from peripheral blood CLL cells
|
Illumina HiSeq 2000,NextSeq 500 | 34 |
Who archives the data?
